Qureight
eDR49Effective DR: 49/100. Below median. Measured by StartupHub.ai. Median 68.Agent39Agent Readiness: 39/100. Below median. Measured by StartupHub.ai. Median 41.Trust74Data Trust: 74/100. Above median. Measured by StartupHub.ai. Median 61.An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.
About
Qureight is a MedTech company that provides an end-to-end AI-powered imaging platform for clinical trials, with a specific focus on lung and heart disease. They leverage 3D deep-learning imaging and AI-powered biomarkers to analyze complex medical images, identify disease progression, and accelerate drug discovery and development for biopharmaceutical companies. The platform aims to improve clinical trial design and efficiency by automating image management and providing precise clinical trial endpoints.
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Biotech
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Drug Discovery
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Leveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.
Shares Biotechnology, Artificial Intelligence
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Drug Discovery
Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
Shares Biotechnology, Drug Discovery
Key facts
- Website
- qureight.com
- Headquarters
- Cambridge, United Kingdom
- Founded
- 2018
- Total funding
- $20M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 29 Jul 2026 | Series B | $20M | Molten Ventures |
Tech stack
Detected on qureight.com, last scanned 21 Oct 2026. Run your own scan
- Compliance
- ISO 27001
- Auth
- Auth0
- Analytics
- Google Tag Manager
- Support
- Zendesk
- CDN
- Cloudflare
- Hosting
- AWS
- Email provider
- Microsoft 365
Qureight scores 27. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
4 reviews from Reddit gathered in one place
CPIX | CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH.
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF.
Data analytics company Qureight has entered into a multi-year strategic research collaboration with AstraZeneca that will use AI models to accelerate research into lung diseases.
Data analytics company Qureight has entered into a multi-year strategic research collaboration with AstraZeneca that will use AI models to accelerate research into lung diseases.
Each quote is copied word for word and links to where it was posted. Promotion and off-topic posts are filtered out.
Frequently asked
Is Qureight trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Qureight is 74 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Qureight raised?
Qureight has raised a total of $20M in funding. The most recent round on record is Series B.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Qureight
